<DOC>
	<DOCNO>NCT00255710</DOCNO>
	<brief_summary>RATIONALE : Giving low dos chemotherapy , fludarabine , radiation therapy donor bone marrow stem cell transplant help stop growth cancer cell . It also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune system help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving cyclophosphamide , mycophenolate mofetil , tacrolimus transplant may stop happen . PURPOSE : This phase I trial study cyclophosphamide and/or mycophenolate mofetil without tacrolimus see best regimen treat patient undergo donor bone marrow stem cell transplant hematologic cancer .</brief_summary>
	<brief_title>Cyclophosphamide and/or Mycophenolate Mofetil With Without Tacrolimus Treating Patients Who Are Undergoing Donor Bone Marrow Peripheral Stem Cell Transplant Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine minimal ( short-duration ) post-transplant immunosuppression regimen comprise cyclophosphamide and/or mycophenolate mofetil without tacrolimus result ≤ 20 % incidence grade II high acute graft-versus-host disease ( GVHD ) patient hematologic malignancy undergo nonmyeloablative allogeneic bone marrow peripheral blood stem cell transplantation HLA-identical related donor . - Determine post-transplant immunosuppression regimen result &lt; 10 % incidence nonengraftment , define &lt; 5 % donor chimerism peripheral blood day 60 , patient . - Determine incidence severity acute GVHD patient treat regimen . - Determine frequency mixed chimerism patient treat regimen . OUTLINE : - Nonmyeloablative allogeneic bone marrow transplantation ( BMT ) peripheral blood stem cell transplantation ( PBSCT ) : Patients receive fludarabine IV day -4 -2 undergo total-body irradiation day -1 . Patients undergo allogeneic BMT day 0 PBSCT day 0 ( day 1 2 , need ) . Patients receive filgrastim ( G-CSF ) begin day 5 continue least day 15 blood count recover . - Sequentially increase level post-transplant immunosuppression : Cohorts patient enrol 1 follow regimen : - Regimen 1 ( post-BMT immunosuppression ) : Patients receive cyclophosphamide IV day 3 . - Regimen 2 ( post-BMT immunosuppression ) : Patients receive mycophenolate mofetil ( MMF ) day 3 twice daily day 4-32 . - Regimen 3 ( post-BMT immunosuppression ) : Patients receive cyclophosphamide IV day 3 4 MMF twice daily day 4-33 . - Regimen 4 ( post-PBSCT immunosuppression ) : Patients receive cyclophosphamide MMF regimen 3 . - Regimen 5 ( post-PBSCT immunosuppression ) : Patients receive cyclophosphamide MMF regimen 3 tacrolimus twice daily day 4-33 . Cohorts approximately 10-20 patient receive sequentially increase level post-transplant immunosuppression minimal ( short-duration ) post-transplant immunosuppression regimen identify . The minimal post-transplant immunosuppression regimen define regimen ≤ 3 10 ≤ 6 20 patient develop grade II high acute graft-versus-host disease AND ≤ 2 10 ≤ 4 20 patient fail engraft 60 day post-transplantation . Once minimal post-transplant immunosuppression regimen identify , additional 10 patient treated regimen . Patients follow 60 day transplantation . PROJECTED ACCRUAL : A total 60 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 follow hematologic malignancy : Stage II III multiple myeloma Amyloidosis Myelofibrosis ≥ 2 follow highrisk feature : Over 55 year age Hemoglobin &lt; 10 g/dL WBC &lt; 3,000/mm^3 OR &gt; 10,000/mm^3 Platelet count &lt; 100,000/mm^3 Cytogenetic abnormality Mycosis fungoides , meet 1 follow criterion : Stage IIB III disease evidence histologic conversion aggressive lymphoma Must demonstrate chemosensitivity Stage IV disease Paroxysmal nocturnal hemoglobinuria Not meet criterion bone marrow transplantation ( BMT ) treatment study Diagnosis 1 follow hematologic malignancy , patient eligible potentially curative allogeneic BMT due endorgan dysfunction , age 65 75 , amount prior chemotherapy : Acute myeloid acute lymphoblastic leukemia Highrisk disease first second ( ) complete remission Relapsed aggressive nonHodgkin 's lymphoma Not eligible autologous standard allogeneic BMT Hodgkin 's lymphoma second complete partial remission Not eligible autologous standard allogeneic BMT Myelodysplastic syndrome myelodysplastic/myeloproliferative disease Any follow subtypes : Refractory anemia excess blast ( RAEB ) RAEB transformation Chronic myelomonocytic leukemia Any morphologic subtype multiple chromosomal abnormality Any subset lifethreatening cytopenia 3 cell line , define platelet count ≤ 20,000/mm^3 , absolute neutrophil count ≤ 500/mm^3 , reticulocyte count ≤ 50,000/mm^3 Meets follow criterion : Less 20 % blast bone marrow biopsy Not eligible standard allogeneic BMT No refractory anemia ring sideroblast No 5q syndrome Stage III IV chronic lymphocytic leukemia Not meet criterion BMT study Chronic myelogenous leukemia first second chronic phase Not meet criterion BMT study treatment Stage III IV indolent small lymphocytic follicular lymphoma Not eligible autologous standard allogeneic BMT active protocol Sidney Kimmel Comprehensive Cancer Center Johns Hopkins Must HLAidentical relate donor available PATIENT CHARACTERISTICS : Performance status ECOG 02 Life expectancy Not specify Hematopoietic See Disease Characteristics Hepatic Bilirubin ≤ 3.0 mg/dL AST ≤ 175 U/L ALT ≤ 200 U/L Renal Creatinine ≤ 3.0 mg/dL Cardiovascular LVEF ≥ 30 % Pulmonary FEV_1 ≥ 40 % predict Forced vital capacity ≥ 40 % predict Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative PRIOR CONCURRENT THERAPY : Chemotherapy See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>graft versus host disease</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>chronic idiopathic myelofibrosis</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory cytopenia multilineage dysplasia</keyword>
	<keyword>primary systemic amyloidosis</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
</DOC>